tm logo
OPZYOS
Live/Pending
FOURTH EXTENSION - GRANTED

granted

on 15 Oct 2024

Last Applicant/ Owned by

1000 Sierra Point Parkway

Brisbane

CA

94005

Serial Number

90702296 filed on 11th May 2021

Registration Number

N/A

Correspondent Address

Marilyn F. Kelly

Marilyn F. Kelly

TRADEMARK DEPT., MAILSTOP D4243

PRINCETON, NJ 08648-4000

United States

Filing Basis

1. intent to use

2. intent to use current

Disclaimer

NO DATA

OPZYOS

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloprol Read More

Classification Information


Class [005]
Pharmaceutical Products


Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely, T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; monoclonal antibodies for therapeutic use for treating viral infections, inflammatory diseases, cardiovascular diseases, auto-immune diseases, blood diseases, and cancers


First Use Date in General

N/A

First Use Date in Commerce

N/A

Mark Details


Serial Number

No 90702296

Mark Type

No Service/Collective Mark

Attorney Docket Number

No 00159817-US

44D Filed

No

44D Current

No

44E filed

No

44E Current

No

66A Filed

No

66A Current

No

Current Basis

No

No Basis

No

Legal History


Show more

Status DateAction Taken
15th Oct 2024SOU EXTENSION 4 FILED
15th Oct 2024SOU EXTENSION 4 GRANTED
15th Oct 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
15th Oct 2024SOU TEAS EXTENSION RECEIVED
15th Mar 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
14th Mar 2024SOU EXTENSION 3 FILED
14th Mar 2024SOU TEAS EXTENSION RECEIVED
14th Mar 2024SOU EXTENSION 3 GRANTED
05th Oct 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
03rd Oct 2023SOU EXTENSION 2 GRANTED